SAFE Or Convertible Note: What You Are Actually Agreeing To
Both instruments postpone the valuation argument, but they treat time, debt and dilution very differently. How each one works and the clauses to read twice.
The first money most startups raise is not a purchase of shares at all. It is a promise of shares later, written on a SAFE or a convertible note, and founders often sign one without fully understanding how it will look on the cap table a year or two down the road.
Both instruments exist to solve the same problem. Early on, nobody can credibly agree on what the company is worth, and pricing a round costs time and legal fees. So the investor hands over cash now, and the decision about how many shares that cash buys is deferred to a future priced round.
How a convertible note works
A convertible note is debt. It has a principal amount, an interest rate and a maturity date. Interest usually accrues rather than being paid in cash, and when a qualifying equity financing happens, the principal plus accrued interest converts into shares of the new round.
Because it is debt, the maturity date matters. If the company has not raised a qualifying round by that date, the noteholder may in principle be able to demand repayment. In practice most holders extend or convert rather than force a young company into default, but the bargaining power sits with them, and a founder renegotiating an overdue note is not negotiating from strength.
Notes also define what counts as a qualified financing, usually by setting a minimum raise size. A small bridge round may not trigger conversion, which can leave notes sitting on the balance sheet longer than anyone expected.
How a SAFE works
A SAFE, short for simple agreement for future equity, was published as a free template by a prominent accelerator and has become the default early instrument for many companies. It is not debt. There is no interest and no maturity date. The investor’s cash converts into equity at the next priced round, or is paid out under defined terms if the company is sold or dissolves first.
The absence of a maturity date is the main attraction for founders. There is no deadline that hands the investor bargaining power. The trade-off is that a SAFE can stay outstanding indefinitely, and its holders have fewer formal rights than a shareholder or a creditor while they wait.
The terms that decide your dilution
Both instruments use the same two levers. A valuation cap sets the maximum valuation at which the investor’s money converts, so if the next round is priced above the cap, the early investor gets more shares than new investors for the same dollar. A discount gives the early investor a percentage off the next round’s price. Many instruments include both, and the investor gets whichever produces more shares.
The bigger question with SAFEs is whether the instrument is pre-money or post-money. A post-money SAFE calculates the holder’s ownership against a valuation that already includes all SAFE money raised. That makes each investor’s percentage easy to predict, but it means every additional SAFE dilutes the founders and existing shareholders rather than the other SAFE holders. Founders who keep raising on post-money SAFEs at the same cap can give away much more of the company than the headline numbers suggest.
Watch for a most-favored-nation clause, which lets an investor adopt better terms you later give someone else, and for side letters granting pro rata rights in future rounds. Neither is unusual, but both carry forward into your next negotiation.
The securities law part
SAFEs and convertible notes are securities. Selling them requires an exemption from SEC registration, most commonly under Regulation D, which typically means selling to accredited investors and filing a Form D notice after the first sale. States can also require notice filings. These are routine steps, but skipping them creates a cleanup job at your next financing.
What to do before you sign
Build a simple model showing ownership after conversion at two or three plausible next-round valuations, including every instrument you have already issued. Do this before you sign, not when a lead investor sends a term sheet.
Keep a running register of every SAFE and note with its cap, discount, pre- or post-money basis, side letters and date. Use standard templates where you can, since investors and lawyers already know them and that saves fees.
If you are choosing between the two, ask yourself how confident you are about the timing of your next priced round. If it is uncertain, a maturity date is a real risk. If it is close, the differences narrow, and the cap you agree to matters far more than the name of the document.
This is general information, not legal advice. Speak to a qualified attorney in your jurisdiction before acting on any of it.
